Contact Us  +(1) 855 8KRANE8  info@kraneshares.com

KURE

KraneShares MSCI All China Health Care Index ETF

Download KURE Presentation

Download Fact Sheet

Investment Strategy:

KURE seeks to measure the performance of MSCI China All Shares Health Care 10/40 Index. The Index is a free float adjusted market capitalization weighted index designed to track the equity market performance of Chinese companies engaged in the health care sector. The securities in the Index include all types of publicly issued shares of Chinese issuers, which are listed in Mainland China, Hong Kong and United States. Issuers eligible for inclusion must be classified under the Global Industry Classification Standard as engaged in the healthcare sector. The issuers included in the Underlying Index may include small-cap, mid-cap and large-cap companies.

China Health Care Sector Highlights:

  • China currently has the fastest growing major healthcare market in the world with a five-year compound annual growth rate of 17%, compared to just 4% in the United States, and -2% in Japan1.
  • China is the second largest healthcare market globally with total healthcare expenditure reaching $594 billion in 20151. A number projected to reach $1.1 trillion by 20202.
  • There is still opportunity for considerable growth in China’s healthcare market with per capita health spending at just $420, compared to an average of over $5,800 for the world’s top eight healthcare markets in terms of per capita expenditure3.
  • China’s aging population, rising incomes and increasing urbanization may provide a sustained catalyst for growth in China’s healthcare sector.

KURE features:

  • Exposure to Chinese companies listed in the Mainland, Hong Kong and United States that are involved in the healthcare industry, specifically: patent and generic pharmaceuticals, hospital administration, biotechnology, medical equipment production, healthcare IT, and traditional Chinese medicine.
  • Exposure to companies that benefit from China’s growing middle class and aging population.
  • Access to leading Chinese pharmaceutical companies which have been recipients of favorable policy and market conditions for research and development and the invention of new medicines and devices.

1.) Major healthcare markets defined as top five global markets by the World Health Organization. Data from the World Health Organization as of 12/31/2015 retrieved 01/29/2018

2.) International Trade Association, "2016 Top Markets Report Pharmaceuticals, 2016". Retrieved 01/26/2018.

3.) Data from IMS Market Prognosis, 10/2016

Fund Details

Data as of 02/20/2018
TickerKURE
Primary ExchangeNYSE
CUSIP922908108
ISINUS9229081081
Net Assets$2,401,572
Total Annual Fund Operating Expense 0.79%
Inception Date02/01/2018
Distribution FrequencySemiannually

Daily Performance

Data as of 02/20/2018
Premium Discount Chart
NAV
Net Asset Value$24.02 
Daily Change 0.35%
Price
Closing Price $0.00 
Daily Change0.00%

Performance History

Distributions
Cumulative %
Data as of: 01/31/2018
Fund NAVClosing PriceIndex
1 Month
3 Month
6 Month
Since Inception
Cumulative %
Data as of quarter end: 12/31/2017
Fund NAVClosing PriceIndex
Since Inception

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted.

Top 10 Holdings

Data as of 02/20/2018
Full Holdings .CSV
RankCompany Name% of Net AssetsTickerShares HeldMarket Value($)
1
CSPC PHARMACEUTICAL GROUP
9.42%1093 HK100,000226,239
2
JIANGSU HENGRUI MEDICINE
8.47%17,937203,371
3
SINO BIOPHARMACEUTICAL
6.99%1177 HK94,000167,969
4
SINOPHARM GROUP CO-H
4.8%1099 HK27,200115,251
5
KANGMEI PHARMACEUTICAL CO
4.42%32,000106,077
6
SHANGHAI FOSUN PHARMACEUT
3.53%13,48384,820
7
SHANGHAI FOSUN PHARMACEUT
2.7%2196 HK11,00064,887
8
CHINA MEDICAL SYSTEM HOLD
2.6%867 HK30,00062,503
9
CHINA RESOURCES PHARMACEU
2.26%3320 HK39,00054,336
10
MEINIAN ONEHEALTH HEALTHC
2.21%15,20052,950

Holdings are subject to change.